Differences in treatment response and survival between HER2(2+)/FISH-positive and HER2(3+) breast cancer patients after dual-target neoadjuvant therapy: a matched case-control study
HER2(2+)/FISH-positive BC patients exhibited worse treatment response and prognosis than HER2(3+) BC patients after dual-target NAT, indicating that HER2 expression level is a crucial factor influencing the therapeutic efficacy and prognosis of BC patients after TCbHP-based dual-target NAT.
Authors
- Xu Zhao (ORCID: https://orcid.org/0000-0001-5393-8906)
- Xuhui Qin
- Yi Ren (ORCID: https://orcid.org/0000-0002-3665-700X)
- Xing Wei (ORCID: https://orcid.org/0000-0002-3035-5633)
- Sicheng Zhou (ORCID: https://orcid.org/0000-0003-0420-2892)
- Chaoyi Wei
- Z. Gong (ORCID: https://orcid.org/0009-0003-0674-5425)
Institutions
- Peking University (CN)
- Jining Traditional Chinese Medicine Hospital (CN)
- Hebei University of Chinese Medicine (CN)
- Peking University First Hospital (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-04-04
- DOI
- https://doi.org/10.3389/fonc.2025.1530793
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Peking University First Hospital
- Peking University